Show simple item record

2018-11-16Zeitschriftenartikel DOI: 10.25646/5833
Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model
dc.contributor.authorNdumnego, Okechukwu C.
dc.contributor.authorKoehler, Susanne M.
dc.contributor.authorCrafford, Jannie E.
dc.contributor.authorBeyer, Wolfgang
dc.contributor.authorvan Heerden, Henriette
dc.date.accessioned2018-12-17T11:04:47Z
dc.date.available2018-12-17T11:04:47Z
dc.date.issued2018-11-16none
dc.identifier.other10.1038/s41598-018-35382-8
dc.identifier.urihttp://edoc.rki.de/176904/5882
dc.description.abstractAnthrax is primarily recognized as an affliction of herbivores with incubation period ranging from three to five days post-infection. Currently, the Sterne live-spore vaccine is the only vaccine approved for control of the disease in susceptible animals. While largely effective, the Sterne vaccine has several problems including adverse reactions in sensitive species, ineffectiveness in active outbreaks and incompatibility with antibiotics. These can be surmounted with the advent of recombinant peptides (non-living) next generation vaccines. The candidate vaccine antigens comprised of recombinant protective antigen (PA), spore-specific antigen (bacillus collagen-like protein of anthracis, BclA) and formaldehyde inactivated spores (FIS). Presently, little information exists on the protectivity of these novel vaccine candidates in susceptible ruminants. Thus, this study sought to assess the immunogenicity of these vaccine candidates in goats and evaluate their protectivity using an in vivo mouse model. Goats receiving a combination of PA, BclA and FIS yielded the highest antibody and toxin neutralizing titres compared to recombinant peptides alone. This was also reflected in the passive immunization experiment whereby mice receiving immune sera from goats vaccinated with the antigen combination had higher survival post-challenge. In conclusion, the current data indicate promising potential for further development of non-living anthrax vaccines in ruminants.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleImmunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse modelnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/5882-5
dc.identifier.doihttp://dx.doi.org/10.25646/5833
dc.type.versionpublishedVersionnone
local.edoc.container-titleScientific Reportsnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.nature.com/articles/s41598-018-35382-8none
local.edoc.container-publisher-nameNature Publishing Groupnone
local.edoc.container-volume8none
local.edoc.container-issue16937none
local.edoc.container-reportyear2018none
local.edoc.container-firstpage1none
local.edoc.container-lastpage10none
dc.description.versionPeer Reviewednone

Show simple item record